Drug group GlaxoSmithKline's (LON:GSK) HIV joint venture on Wednesday reported positive results from a study of its Triumeq treatment.
ViiV Healthcare, in which GSK is a shareholder along with Pfizer and Shionogi, said new Phase IIIb/IV data showed switching to a once-daily version of Triumeq maintains HIV viral suppression.
In the study, patients switched from an anti-retroviral therapy (ART) to the once-daily, fixed-dose Triumeq, otherwise known as an abacavir/lamivudine/dolutegravir-based regimen, in virologically suppressed adults with HIV-1.
No patients had protocol-defined virologic failure and the treatment satisfaction score improved significantly more for those patients switching to once-daily abacavir/dolutegravir/lamivudine from their established regimen.
ViiV's chief scientific and medical officer John Pottage said: "For clinicians, choosing among antiretroviral therapies now involves balancing efficacy with factors such as tolerability, dosing, ability to use with other medications, and resistance profile.
"These data support the use of once-daily abacavir/dolutegravir/lamivudine as a treatment option in the switch setting for appropriate patients."
Shares in GlaxoSmithKline rose 17.5p to 1264.5p.